• 1
    Roy CC, Weber AM, Morin CL, et al. Hepatobiliary disease in Cystic Fibrosis: A survey of current issues and concepts. J Pediatr Gastroenterol Nutr 1982; 1: 469478.
  • 2
    Tanner MS. Liver and biliary problems in cystic fibrosis. J Royal Soc Med 1992; 85: 2024.
  • 3
    Colombo C, Battezzati PM, Podda M: Hepatobiliary disease in cystic fibrosis. Semin Liver Dis 1994; 14: 259269.
  • 4
    Conn JA, Strong TV, Picciotto MR, Nairn AC, Collins FS, Fitz JG. Localization of the cystic fibrosis transmembrane conductance regulator in human bile duct epithelial cells. Gastroenterology 1993; 105: 18571864.
  • 5
    Fitz Simmons SC. The changing epidemiology of cystic fibrosis. J Pediatr 1993; 122: 19.
  • 6
    Scott-Jupp R, Lama M, Tanner MS. Prevalence of liver disease in cystic fibrosis. Arch Dis Child 1991; 66: 698701.
  • 7
    Williams SGJ, Hayller KM, Hodson ME, Westaby D. Prognosis in cystic fibrosis. N Engl J Med 1992; 325: 12441254.
  • 8
    Colombo C, Setchell KDR, Podda M, Crosignani A, Roda A, Curcio L, Giunta A. The effects of ursodeoxycholic acid therapy in liver disease associated with cystic fibrosis. J Pediatr 1990; 117: 482489.
  • 9
    Cotting J, Lentze M, Reichen J. Effects of ursodeoxycholic acid treatment on nutrition and liver function in patients with cystic fibrosis and longstanding cholestasis. Gut 1990; 31: 918921.
  • 10
    Nakagawa M, Colombo C, Setchell KDR. Comprehensive study of the biliary bile acid composition of the patients with cystic fibrosis and associated liver disease before and after UDCA administration. Hepatology 1990; 12: 322334.
  • 11
    Bittner P, Posselt HG, Sailer T, Ott H, Magdorf K, Wahn U, Arleth S, et al. The effect of treatment with ursodeoxycholic acid in cystic fibrosis and hepatopathy: Results of a placebo-controlled study. In: PaumgartnerG, StiehlA, GerokW, eds. Bile acids as therapeutic agents—from basic science to clinical practice. Dordrecht: Kluwer Academic Publishers, 1991: 345348.
  • 12
    Galabert C, Montet JC, Lengrand D, Lecuire A, Sotta C, Figarella C, Chazalette JP. Effects of ursodeoxycholic acid on liver function in patients with cystic fibrosis and chronic cholestasis. J Pediatr 1992; 121: 138141.
  • 13
    Reichen J, Paumgartner G, Cotting J, Lentze MJ. Effect of long-term ursodeoxycholate on liver function, nutritional state and serum bile acids in cystic fibrosis with long-standing cholestasis. In: PaumgartnerG, StiehlA, GerokW, eds. Bile acids as therapeutic agents—from basic science to clinical practice. Dordrecht: Kluwer Academic Publishers, 1991: 335344.
  • 14
    Colombo C, Castellani MR, Balistreri WF, Seregni E, Assaisso ML, Giunta A. Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease. Hepatology 1992; 15: 677684.
  • 15
    Cotting J, Dufour JF, Lentze MJ, Paumgartner G, Reichen J. Ursodeoxycholate in the treatment of cholestasis in cystic fibrosis: A 2-year experience and review of the literature. In: LentzeMJ and ReichenJ, eds. Paediatric cholestasis: novel approaches to treatment. Dordrecht: Kluwer Academic Publishers, 1992: 345354.
  • 16
    Colombo C, Crosignani A, Assaisso ML, Battezzati PM, Podda M, Giunta A, Zimmer-Nechemias L, Setchell KDR. Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: A dose-response study. Hepatology 1992; 16: 924930.
  • 17
    O'Brien S, Fitzgerald MX, Hegarty JE. A controlled trial of ursodeoxycholic acid treatment in cystic fibrosis-related liver disease. Eur J Gastroenterol Hepatol 1992; 4: 857863.
  • 18
    Heuman DM. Hepatoprotective properties of ursodeoxycholic acid [Editorial]. Gastroenterology 1993; 104: 18651870.
  • 19
    Thompson GN. Excessive fecal taurine loss predisposes to taurine deficiency in cystic fibrosis. J Pediatr Gastroenterol Nutr 1988; 7: 214217.
  • 20
    Shwachman H, Kulczycki LL. Long-term study of 105 patients with cystic fibrosis. Am J Dis Child 1958; 96: 615.
  • 21
    Ramsey BW, Boat TF, for the Consensus Group. Outcome measures for clinical trials in cystic fibrosis. J Pediatr 1994; 124: 177192.
  • 22
    Roda A, Girotti S, Lodi S, Preti S. Development of a sensitive enzyme immunoassay for plasma and salivary steroids. Talanta 1984; 31: 895900.
  • 23
    Van de Kamer JH, ten Bokkel Huinink H, Weyers HA. Rapid method for the determination of fat in feces. J Biol Chem 1949; 177: 347355.
  • 24
    Winer BJ. Statistical principles in experimental design. 2nd ed. New York: McGraw-Hill 1971, Chap. 5–6.
  • 25
    Conover WJ, Iman RL. Rank transformations as a bridge between parametric and nonparametric statistics. Am Stat 1981; 35: 124133.
  • 26
    Anonymous. Bile acid therapy in the 1990s. Lancet 1992; 340: 12601261.
  • 27
    Poupon RE, Balkau B, Eschwège E, Poupon R and The UDCA-PBC Study Group. A multicenter controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 1991; 324: 15481554.
  • 28
    Beuers U, Spengler U, Kruis W, Aydemir U, Wiebecke B, Heldwein W, Weinzierl M, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: A placebo-controlled trial. Hepatology 1992; 16: 707714.
  • 29
    Merli M, Bertasi S, Servi R, Diamanti S, Martino F, De Santis A, et al. Effect of a medium dose of Ursodeoxycholic acid with or without taurine supplementation on the nutritional status of patients with cystic fibrosis: a randomized, placebo-controlled, crossover trial. J Pediatr Gastroenterol Nutr 1994; 19: 198203.
  • 30
    Perdigoto R, Wiesner RH. Progression of primary biliary cirrhosis with Ursodeoxycholic acid therapy. Gastroenterology 1992; 102: 13891391.
  • 31
    Weber AM, Roy CC. Bile acid metabolism in children with cystic fibrosis. Acta Paediatr 1985; 317(suppl): 915.
  • 32
    Anonymous. Taurine supplementation in cystic fibrosis. Nutrition Reviews 1988; 46: 257258.
  • 33
    Smith LJ, Lacaille F, Lepage G, Ronco N, Lamarre A, Roy CC. Taurine decreases fecal fatty acid and sterol excretion in cystic fibrosis. A randomized double-blind trial. Am J Dis Child 1991; 145: 14011404.
  • 34
    Belli DC, Levy E, Darling P, Leroy C, Lepage G, Giguère R, Roy CC. Taurine improves the absorption of a fat meal in patients with cystic fibrosis. Pediatrics 1987; 80: 517523.
  • 35
    Darling PB, Lepage G, Leroy C, Masson P, Roy CC. Effects of taurine supplements on fat absorption in cystic fibrosis. Pediatr Res 1985; 19: 578582.
  • 36
    Colombo C, Arlati S, Curcio L, Garatti M, Corbetta C, Giunta A. Effect of taurine supplementation on fat and bile acid absorption in patients with cystic fibrosis. Scand J Gastroenterol 1988; 23(suppl 143): 517523.
  • 37
    Mancini G, Carbonara A, Heremans JF. Immunochemical quantitation of antigens by immunodiffusion. Immunochemistry 1965; 2: 235240.